摘要
目的探讨重组人血管内皮抑制素联合m FOLFOX化疗方案在晚期肝癌中的应用效果。方法将我院2014年5月—2016年1月收治的60例晚期肝癌患者根据计算机SPSS 19.0统计学软件随机、均等分组,对照组(30例)患者予以m FOLFOX方案化疗,观察组(30例)患者在此基础上静脉滴注重组人血管内皮抑制素进行疾病干预,观察两组患者的治疗效果。结果对照组总有效率为46.7%,观察组总有效率为73.3%,观察组总有效率高于对照组(P<0.05)。结论重组人血管内皮抑制素联合m FOLFOX化疗方案在晚期肝癌中的应用效果突出。
Objective To investigate the application effect of recombinant human endostatin combined with mFOLFOX chemotherapy for advanced hepatocellular carcinoma. Methods 60 cases of advanced liver cancer patients in our hospital from May 2014 to January 2016 according to the computer statistical software SPSS 19.0 randomized, equal groups, the control group （30 cases） were treated with mFOLFOX chemotherapy, the observation group （30 cases） were on the basis of disease intervention for patients with intravenous infusion of recombinant human endostatin, observe the therapeutic effect of two groups. Results The total effective rate of control group was 46.7%, the total efficiency of the observation group was 73.3%, the total efficiency of the observation group was significantly higher than the control group （P〈0.05）. Conclusion The application effect of recombinant human endostatin combined with mFOLFOX chemotherapy for advanced hepatocellular carcinoma is prominent.
出处
《中国继续医学教育》
2017年第5期160-162,共3页
China Continuing Medical Education
